Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
The platform is being introduced to expand access to treatments for people living with chronic conditions
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Subscribe To Our Newsletter & Stay Updated